Biozenta Oncology, an India-based manufacturer of anti-cancer medications, has announced plans to establish a pharmaceutical and clinical healthcare in Tanzania, aimed at improving access to affordable cancer treatments and medications
Speaking at the ongoing Pharma and Medical Exhibition in Dar es Salaam, the global company’s Representative emphasized that Biozenta is guided by the motto “Human helping a human,” underlining its mission to deliver hope and solutions to cancer patients.
The firm, which recently opened offices in Kenya and has gained regulatory approvals across East Africa, plans to provide oncology medicines including tablets, capsules, liquids, and lyophilized injections locally.
It also pursues ongoing clinical development, expanding existing drug lines, and generating new clinical data to strengthen treatment options, that are distributed around the globe.
Established on strict adherence to global cGMP standards with a “zero tolerance” policy on product stability and quality, Biozenta aims to address cancers including the breast, liver, lung, brain, and kidney cancers.
Speaking about the local production, the company says, will lower treatment costs and decrease the need for patients to travel abroad.
With backing from bodies including the Tanzania Medicines and Medical Devices Authority (TMDA) and the Tanzania Investment Centre (TIC), Biozenta hopes to complete foundational work on its Tanzanian future in clinical services within the next few years to come.
Tanzania records an estimated 40,000 new cancer cases each year, a growing health challenge that has strained the country’s treatment capacity and forced many patients to seek costly care abroad.